Elexacaftor/tezacaftor/ivacaftor Treatment Reduces Airway Inflammation in Cystic Fibrosis.

ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in some treated individuals, indicating an ongoing need to optimize other treatments in a subset of patients. This article is protected by copyright. All rights reserved.